Go to content
May 27, 2026

Releasing the Brakes on CAR T-Cell Therapy with DARPin-conjugated LNP for In Vivo Delivery

Designing an in vivo cell therapy that appropriately balances efficacy and safety remains a significant challenge; however DARPin-conjugated LNP have shown promise on both counts in preclinical studies.

Designing an in vivo cell therapy that appropriately balances efficacy and safety remains a significant challenge; however DARPin-conjugated LNP have shown promise on both counts in preclinical studies.